Then, the current clinical trials evaluating CYP46A1 modulations will be described, after which a discussion of the most recent studies aimed at understanding how this single enzyme, CYP46A1, can represent a common therapeutic target for various brain diseases. This evidence concerns the gene CYP46A1 and brain disorder.